FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileCerevel Therapeutics Holdings, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
CERE
Cerevel Therapeutics Holdings, Inc. Stock AnalysisComprehensive stock analysis for Cerevel Therapeutics Holdings, Inc. (CERE) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisCERE
CERE
Cerevel Therapeutics Holdings, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
CERE
  1. Home
  2. Stocks
  3. Cerevel Therapeutics Holdings, Inc.

Cerevel Therapeutics Holdings, Inc.

🇺🇸CERE•NASDAQ

Cerevel Therapeutics Holdings, Inc.

🇺🇸CERE•NASDAQ
Market cap
$8.19B
Sentiment

Your view on CERE

Mkt Cap
$8.19B
Sentiment
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Cerevel Therapeutics Holdings, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Ronald C. Renaud Jr.,
Headquarters
US
Industry
Biotechnology
Sector
Healthcare
CEO
Ronald C. Renaud Jr.,
Headquarters
US
Description

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases.

It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety.

The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I clinical trial for the treatment of substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder; and CVL-047, selective PDE4 inhibitor for the treatment of major depressive disorder and substance use disorder.

It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and an LRRK2 inhibitor program to address disease progression in Parkinson's. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Financial Data

Stock Data

Price chart, volume, and trading data.

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for Cerevel Therapeutics Holdings, Inc. from FRC's valuation model, read against the market price. CERE last traded at $44.96; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Cerevel Therapeutics Holdings, Inc.. Starting points for Cerevel Therapeutics Holdings, Inc.: EPS -$2.67, beta 1.41 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Cerevel Therapeutics Holdings, Inc.. Cerevel Therapeutics Holdings, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Cerevel Therapeutics Holdings, Inc.. Trailing twelve-month EPS for Cerevel Therapeutics Holdings, Inc. stands at -$2.67. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 18, 2026 · USD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Current price

—

live quote

Analysts' target

$33.50

average of analysts' targets

 

$33.50

Low $27.00

Median $33.50

High $40.00

 

Analyst Ratings

Hold16 ratings
  • Strong Buy0
  • Buy6
  • Hold10
  • Sell0
  • Strong Sell0

Earnings Estimate

EPSCurrent QtrJun 2024Next QtrSep 2024Current YearFY Dec 2024Next YearFY Dec 2025
Avg. estimate$0.00-$0.73-$2.91-$3.15
Low estimate$0.00-$0.73-$3.59-$3.54
High estimate$0.00-$0.73-$1.98-$2.81
No. of analysts1143
Year-ago EPS——-$2.67—
Growth——-9.1%—

Revenue Estimate

RevenueCurrent QtrJun 2024Next QtrSep 2024Current YearFY Dec 2024Next YearFY Dec 2025
Avg. estimate$0.00$0.00$0.00$13.52M
Low estimate$0.00$0.00$0.00$13.52M
High estimate$0.00$0.00$0.00$13.52M
No. of analysts0003
Year-ago revenue——$0.00—
Growth————
Recent analyst actions15 rating and price-target changes, latest Feb 16, 2024 — with the analyst, firm and source

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from Benzinga, Pulse 2.0; as of Nov 18, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Cerevel Therapeutics Holdings, Inc.. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold CERE13 companies
Compare CERE with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis

Peer companies

Market cap

  • ROIVRoivant Sciences Ltd.Biotechnology$28.0B

More Biotechnology companies

  • VXRTVaxart, Inc.OTC$129M
  • VYGRVoyager Therapeutics, Inc.NASDAQ$101M
  • WHWKWhitehawk Therapeutics IncNASDAQ$178M
  • WINTWindtree Therapeutics, Inc.NASDAQ$2M
  • WSNAFWesana Health Holdings Inc.OTC$341,000
  • WVEWave Life Sciences Ltd.NASDAQ$566M
  • WXIBFWuXi Biologics (Cayman) Inc.OTC$21.3B
  • WXXWYWuXi Biologics (Cayman) Inc.OTC$21.7B
  • XAGELongevity Health Holdings Inc.OTC$415,447
  • XBIOXenetic Biosciences, Inc.NASDAQ$3M
  • XBITXBiotech Inc.NASDAQ$56M
  • XCURExicure, Inc.NASDAQ$7M
Open Comparable Analysis
Ownership & News

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Cerevel Therapeutics Holdings, Inc. executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Cerevel Therapeutics Holdings, Inc.. Coverage tracks Cerevel Therapeutics Holdings, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Cerevel Therapeutics Holdings, Inc.

CERE Analysis
Weak
Past1
Growth2
Health3
Profit1
Value1

News

Latest Market News